From the perspective of the Chinese health care system, it is unlikely that the use of atezolizumab in the adjuvant treatment of Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy (PD-L1 TC ≥ 1% stage II-IIIA group, all-stage randomized II-IIIA group, ITT group) is cost-effective. This evidence concerns the gene CD274 and non-small cell lung carcinoma.